

Resources from: **COVID-19 Prevention for Special Populations**

- Frequently Asked Questions on the Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab) for Pre-exposure Prophylaxis (PrEP) of COVID-19 (fda.gov): <https://www.fda.gov/media/154703/download>
- NIH Guidelines on Prevention of SARS-CoV-2 Infection: <https://www.covid19treatmentguidelines.nih.gov/overview/prevention-of-sars-cov-2/>
- FDA News Release: FDA Authorizes New Long-Acting Monoclonal Antibodies for Pre-exposure Prevention of COVID-19 in Certain Individuals: <https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-long-acting-monoclonal-antibodies-pre-exposure>
- Evusheld Fact Sheet for Healthcare Providers: <https://www.fda.gov/media/154701/download>
- Evusheld Fact Sheet for Patients and Caregivers: <https://www.fda.gov/media/154702/download>
- CMS Billing: COVID-19 Vaccines and Monoclonal Antibodies: <https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies>
- HRSA Reimbursement: <https://www.hrsa.gov/coviduninsuredclaim>
- HPoP: Health Partner Order Portal (cdc.gov): <https://vpop.cdc.gov/provider/signin/>
- MedWatch - FORM FDA 3500: <https://www.fda.gov/media/76299/download>
- Evusheld Information and Locations: https://msdh.ms.gov/msdhsite/_static/14,24118,420,878.html

February 2022

Mississippi State Department of Health